Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 7/20 | 0.46 |
| ▸ | ICMT | O60725 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31017607 | 0.90 | LMNA (0.56) | LMNAIDO1CNR2ATMMEN1 | |
| SCHEMBL18555549 | 0.84 | ICMT (0.42) | LMNAICMTCNR2MEN1KMT2A | |
| SCHEMBL19236926 | 0.83 | CFD (0.45) | LMNAIDO1CNR2MEN1KMT2A | |
| SCHEMBL18562180 | 0.82 | ICMT (0.48) | LMNAIDO1ICMTCNR2PLA2G4A | |
| SCHEMBL20329592 | 0.81 | ICMT (0.51) | LMNAICMTMEN1KMT2APLA2G4A | |
| SCHEMBL18555583 | 0.81 | KRAS (0.49) | LMNAIDO1CNR2MEN1KMT2A | |
| SCHEMBL18611175 | 0.80 | ICMT (0.39) | LMNAICMTCNR2MEN1KMT2A | |
| SCHEMBL18611186 | 0.80 | ICMT (0.48) | LMNAICMTCNR2MEN1KMT2A | |
| SCHEMBL18555409 | 0.78 | PLA2G4A (0.40) | LMNAICMTCNR2MEN1KMT2A | |
| SCHEMBL18549620 | 0.78 | IDO1 (0.49) | LMNAIDO1CNR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | LMNA 1125/4885IDO1 2501/4885ICMT 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.